Previous Close | 102.57 |
Open | 102.70 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 102.28 - 103.00 |
52 Week Range | 92.19 - 108.78 |
Volume | |
Avg. Volume | 1,580,248 |
Market Cap | 209.836B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 23.37 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.78 (3.67%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | N/A |
Q1 2024 Legend Biotech Corp Earnings Call
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.